BCM
ATRS

Bayesian Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Bayesian Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-35,600
Closed -$84K – 866
2020
Q1 		$84K Buy
35,600
+13,128
+58% +$44.7K 0.02% 689
2019
Q4 		$106K Buy
+22,472
New +$92K 0.02% 564

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Bayesian Capital Management's ATRS Position: Q2 2020 in Review

Bayesian Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2020, closing a stake of 35,600 shares — an estimated $84K sold.

Bayesian Capital Management first reported a position in ATRS in Q4 2019 and held it in 2 quarters. The position peaked at $106K in Q4 2019. 159 funds tracked by Wall St. Rank hold ATRS as of Q2 2020.

  • Bayesian Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 35,600 Antares Pharma, Inc. shares in Q2 2020, an estimated $84K.
  • Bayesian Capital Management first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 2 quarters.
  • Bayesian Capital Management's Antares Pharma, Inc. position peaked at $106K in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2020.

Based on Bayesian Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.